Invega Hafyera Approved for Twice-Yearly Treatment of Schizophrenia
Results showed that at the end of the 12-month period, treatment with Invega Hafyera was found to be noninferior to Invega Trinza with regard to the primary endpoint.
Schizophrenia
Genetic Risk Not Better for Predicting Schizophrenia Outcomes
For adults with schizophrenia and related psychotic disorders, the polygenic risk score does not improve the performance of predictive models for outcomes.
Application for Long-Acting Schizophrenia Treatment Accepted for Review
Patients treated with the investigational subcutaneous risperidone injection experienced a statistically significant delay in the time to relapse.
Cognitive Remediation Benefits Patients With Schizophrenia
Cognitive remediation is effective for both cognitive and functional outcomes among patients with schizophrenia.
Increased Risk for Death by Suicide in Young Adults With Schizophrenia
Investigators sought to describe suicide mortality rates and correlates among adults with schizophrenia across the lifespan.
Model May Identify Schizophrenia Cases by DNA Methylation in Blood
A machine learning case-control classifier can identify schizophrenia based on DNA methylation in the blood.
Genetic Risk for Psychiatric Disorders Linked to Brain Changes
Polygenic risk scores for bipolar disorder and schizophrenia are associated with ventromedial prefrontal cortex (vmPFC) structure and function.
Acceptability of Assessment App Low in Schizophrenia Patients
Acceptability of a passive smartphone-based ecological momentary assessment (EMA) app is relatively low among individuals with schizophrenia spectrum disorders.
Care Disparities Seen for COVID-19 Patients With, Without Schizophrenia
There are disparities in health and health care between hospitalized COVID-19 patients with schizophrenia and without severe mental illness.
Brexpiprazole Provides Short- and Long-Term Benefits in Schizophrenia
The goal of the researchers was to describe the short- and long-term effects of brexpiprazole on Positive and Negative Syndrome Scale (PANSS) “Marder factors.”
- Loading...
Loading...
Next post in Neurobehavioral Disorders
Loading... 
Loading...